New hypertension drug shows promise in early safety trial

NCT ID NCT06905327

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This early-stage study tested a new drug called QCZ484 in 56 healthy volunteers and people with mild hypertension. The main goal was to check safety and how the body handles the drug. Participants received a single injection of either QCZ484 or a placebo, and researchers monitored for side effects and lab changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: QCZ484
What this could lead to: If successful, this could lead to a new treatment option for mild hypertension.
What could go wrong: This is an early Phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MILD HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign essential hypertension essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MILD HYPERTENSION

Contacts and locations

Locations

Novartis Investigative Site

Herston, Queensland, 4006, Australia
Novartis Investigative Site

Morayfield, Queensland, 4506, Australia
Novartis Investigative Site

Adelaide, 5000, Australia
Novartis Investigative Site

Auckland, 0622, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.